GB201820725D0 - Pyrrolobenzodiazepine resistance - Google Patents

Pyrrolobenzodiazepine resistance

Info

Publication number
GB201820725D0
GB201820725D0 GBGB1820725.8A GB201820725A GB201820725D0 GB 201820725 D0 GB201820725 D0 GB 201820725D0 GB 201820725 A GB201820725 A GB 201820725A GB 201820725 D0 GB201820725 D0 GB 201820725D0
Authority
GB
United Kingdom
Prior art keywords
pyrrolobenzodiazepine
resistance
pyrrolobenzodiazepine resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1820725.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADC Therapeutics SA
MedImmune Ltd
Original Assignee
ADC Therapeutics SA
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADC Therapeutics SA, MedImmune Ltd filed Critical ADC Therapeutics SA
Priority to GBGB1820725.8A priority Critical patent/GB201820725D0/en
Publication of GB201820725D0 publication Critical patent/GB201820725D0/en
Priority to PCT/EP2019/086079 priority patent/WO2020127573A1/en
Priority to US17/414,622 priority patent/US20220347309A1/en
Priority to EP19824317.2A priority patent/EP3899048A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
GBGB1820725.8A 2018-12-19 2018-12-19 Pyrrolobenzodiazepine resistance Ceased GB201820725D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB1820725.8A GB201820725D0 (en) 2018-12-19 2018-12-19 Pyrrolobenzodiazepine resistance
PCT/EP2019/086079 WO2020127573A1 (en) 2018-12-19 2019-12-18 Pyrrolobenzodiazepine resistance
US17/414,622 US20220347309A1 (en) 2018-12-19 2019-12-18 Pyrrolobenzodiazepine resistance
EP19824317.2A EP3899048A1 (en) 2018-12-19 2019-12-18 Pyrrolobenzodiazepine resistance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1820725.8A GB201820725D0 (en) 2018-12-19 2018-12-19 Pyrrolobenzodiazepine resistance

Publications (1)

Publication Number Publication Date
GB201820725D0 true GB201820725D0 (en) 2019-01-30

Family

ID=65146947

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1820725.8A Ceased GB201820725D0 (en) 2018-12-19 2018-12-19 Pyrrolobenzodiazepine resistance

Country Status (1)

Country Link
GB (1) GB201820725D0 (en)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58180487A (en) 1982-04-16 1983-10-21 Kyowa Hakko Kogyo Co Ltd Antibiotic dc-81 and its preparation
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2007044515A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
WO2007085930A1 (en) 2006-01-25 2007-08-02 Sanofi-Aventis Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
WO2011130616A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines used to treat proliferative diseases
WO2011130613A1 (en) 2010-04-15 2011-10-20 Seattle Genetics, Inc. Targeted pyrrolobenzodiazapine conjugates
WO2014057119A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2014057113A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine - anti-psma antibody conjugates
WO2014057117A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2016166301A1 (en) 2015-04-15 2016-10-20 Van Berkel Patricius Hendrikus Cornelis Site-specific antibody-drug conjugates
WO2016166299A1 (en) 2015-04-15 2016-10-20 Van Berkel Patricius Hendrikus Cornelis Site-specific antibody-drug conjugates
WO2018146189A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2018146199A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58180487A (en) 1982-04-16 1983-10-21 Kyowa Hakko Kogyo Co Ltd Antibiotic dc-81 and its preparation
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2007044515A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
WO2007085930A1 (en) 2006-01-25 2007-08-02 Sanofi-Aventis Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
WO2011130616A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines used to treat proliferative diseases
WO2011130613A1 (en) 2010-04-15 2011-10-20 Seattle Genetics, Inc. Targeted pyrrolobenzodiazapine conjugates
WO2014057119A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2014057113A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine - anti-psma antibody conjugates
WO2014057117A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2016166301A1 (en) 2015-04-15 2016-10-20 Van Berkel Patricius Hendrikus Cornelis Site-specific antibody-drug conjugates
WO2016166299A1 (en) 2015-04-15 2016-10-20 Van Berkel Patricius Hendrikus Cornelis Site-specific antibody-drug conjugates
WO2018146189A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2018146199A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates

Non-Patent Citations (68)

* Cited by examiner, † Cited by third party
Title
"Genbank", Database accession no. AAA60209
"Genbank", Database accession no. AAC50348
"Genbank", Database accession no. AAF23613
"Genbank", Database accession no. AAH32229
"Genbank", Database accession no. AF181722
"Genbank", Database accession no. AK026467
"Genbank", Database accession no. BAB15489
"Genbank", Database accession no. CAA76847
"Genbank", Database accession no. CAA78163
"Genbank", Database accession no. M76125
"Genbank", Database accession no. M99487
"Genbank", Database accession no. NM_000417
"Genbank", Database accession no. NM_001178098
"Genbank", Database accession no. NP_000408
"Genbank", Database accession no. NP_001171569
"Genbank", Database accession no. U40434
"Genbank", Database accession no. Z12172
AMBUDKAR ET AL., AN. R. PHAR. &TOX., vol. 39, 1999, pages 361 - 398
ANGEW CHEM. INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186
ANTONOW, D.; THURSTON, D.E., CHEM. REV., vol. 111, no. 4, 2011, pages 2815 - 2864
ARCE VARGAS ET AL., IMMUNITY, vol. 46, 2017, pages 1 - 10
ARIMA ET AL., J. ANTIBIOTICS, vol. 25, 1972, pages 437 - 444
BOSE, TETRAHEDRON, vol. 48, 1992, pages 751 - 758
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 15663-27-1
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 391210-10-9
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 41575-94-4
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 51-21-8
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 85622-93-1
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
EASTMAN A. ET AL., BIOCHEMISTRY, vol. 27, no. 13, 1988, pages 4730 - 4734
FIELDING A., HAEMATOLOGICA, vol. 95, no. 1, January 2010 (2010-01-01), pages 8 - 12
GREEN SK., ANTICANCER DRUG DES., vol. 14, no. 2, 1999, pages 153 - 168
GREGSON ET AL., J. MED. CHEM., vol. 44, 2001, pages 1161 - 1174
GREGSON, CHEM. COMMUN., 1999, pages 797 - 798
HAENISCH ET AL., BR J CLIN PHARMACOL., vol. 77, no. 4, pages 587 - 596
HARA, J. ANTIBIOTICS, vol. 41, 1988, pages 702 - 704
HOCHLOWSKI, J. ANTIBIOTICS, vol. 40, 1987, pages 145 - 148
HURLEY; NEEDHAM-VANDEVANTER, ACC. CHEM. RES., vol. 19, 1986, pages 230 - 237
ITOH ET AL., J. ANTIBIOTICS, vol. 41, 1988, pages 1281 - 1284
JANEWAY, C; TRAVERS, P.; WALPORT, M.; SHLOMCHIK: "ImmunoBiology", 2001, GARLAND PUBLISHING
KAVALLARIS M. ET AL., J. CLIN. INVEST., vol. 100, no. 5, 1997, pages 1282 - 1293
KOHLER, NATURE, vol. 256, 1975, pages 495
KOHN: "Antibiotics II!", 1975, SPRINGER-VERLAG, pages: 3 - 11
KONISHI, J. ANTIBIOTICS, vol. 37, 1984, pages 200 - 206
KUMINOTO, J. ANTIBIOTICS, vol. 33, 1980, pages 665 - 667
LANGLEY; THURSTON, J. ORG. CHEM., vol. 52, 1987, pages 91 - 97
LEBER, J. AM. CHEM. SOC., vol. 110, 1988, pages 2992 - 2993
LEIMGRUBER ET AL., J. AM. CHEM. SOC., vol. 87, 1965, pages 5791 - 5793
LEIMGRUBER, J. AM. CHEM. SOC., vol. 87, 1965, pages 5793 - 5795
LONBERG, CURR. OPINION, vol. 20, no. 4, 2008, pages 450 - 459
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
MENETRIER-CAUX, C., TARG ONCOL, vol. 7, 2012, pages 15 - 28
MILLER, JOUR, OF IMMUNOLOGY, vol. 170, 2003, pages 4854 - 4861
MORIN PJ., DRUG RESISTANCE UPDATES, vol. 6, no. 4, 2003, pages 169 - 172
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
SETHI T., NATURE MED., vol. 5, no. 6, 1999, pages 662 - 668
SHANKER ET AL., LUNG CANCER: TARGETS AND THERAPY, vol. 1, 2010, pages 23 - 36
SHIMIZU, J. ANTIBIOTICS, vol. 29, 1982, pages 2492 - 2503
SILVER ET AL., BMC MOL BIOL., vol. 7, 2006, pages 33
SPANSWICK VJ; HARTLEY JM; HARTLEY JA: "Measurement of DNA interstrand crosslinking in individual cells using the Single Cell Gel Electrophoresis (Comet) assay", METHODS MOL BIOL., vol. 613, 2010, pages 267 - 82
TAKEUCHI ET AL., J. ANTIBIOTICS, vol. 29, 1976, pages 93 - 96
TANAKA, A. ET AL., CELL RES., vol. 27, no. 1, January 2017 (2017-01-01), pages 109 - 118
THURSTON ET AL., CHEM. BRIT, vol. 26, 1990, pages 767 - 772
THURSTON, CHEM. REV., vol. 1994, 1994, pages 433 - 465
TOWNSEND DM. ET AL., ONCOGENE, vol. 22, no. 47, 2003, pages 7369 - 7375
TSUNAKAWA ET AL., J. ANTIBIOTICS, vol. 41, 1988, pages 1366 - 1373
VOLPE D., EXPERT OPINION ON DRUG DISCOVERY, vol. 11, no. 1, 2016, pages 91 - 103
XIE H., ACTA BIOCHIM BIOPHYS SIN., vol. 40, no. 4, April 2008 (2008-04-01), pages 269 - 77

Similar Documents

Publication Publication Date Title
GB201914271D0 (en) Bush
IL269945B (en) Pyrrolobenzodiazepine conjugates
IL272625A (en) Pyrrolobenzodiazepine conjugates
CA187535S (en) Seat
CA188126S (en) Stool
AU201816010S (en) Chair part
GB201701480D0 (en) Disease resistance
GB201801634D0 (en) #
GB2571905B (en) Disrupter
FI3627028T3 (en) Fitting
GB201807046D0 (en) Combination
GB201820725D0 (en) Pyrrolobenzodiazepine resistance
GB201904342D0 (en) Pyrrolobenzodiazepine resistance
GB201817088D0 (en) Pyrrolobenzodiazepine conjugates
GB201817110D0 (en) Pyrrolobenzodiazepine conjugates
GB201808417D0 (en) Copolymer
ZA201902776B (en) Recumbent vehicle
GB201813472D0 (en) Copolymer blends
HK1250359A1 (en) Seat
AU201811477S (en) Seat
AU201811473S (en) Seat
AU201811472S (en) Seat
GB201807887D0 (en) Combination
GB201800216D0 (en) Sit
GB201800215D0 (en) Sit

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)